AI-Driving Nanobody Drug Development

Next-Generation Biotherapeutic Platform: AI-Engineered Single-Domain Antibodies
Unlocking High-Value Oncology Targets via an Investor-Ready, Validated Asset Pipeline.
NBRL has bridged the gap between generative AI and scalable, translation-ready therapeutics. By replacing traditional, slow immunization methods with proprietary machine-learning architectures, we design advanced single-domain antibodies VHH against high-value, complex targets in fractions of the traditional timeline.
Our business model is built for rapid value creation, offering a robust pipeline of pre-validated candidates ready for license-out, co-development, and strategic pharmaceutical partnerships.

Our Platform Capabilities
We have engineered a closed-loop platform that bypasses biological limitations to deliver optimized, developer-ready molecules from scratch.
• Proprietary De Novo Generation: Our generative frameworks construct novel candidate sequences targeting complex configurations without requiring animal immunization.
• Intelligent In Silico Optimization: Advanced predictive loops simultaneously refine binding affinity, stability, and human compatibility, reducing downstream lab screening cycles from months to days.
• Targeted Multi-Epitope Engagement: Automated workflows coordinate multi-faceted design criteria, allowing us to engineer multi-specific binders with exceptional functional profiles.
• Early-Stage Developability Safeguards: Every candidate undergoes computational profiling at the sequence level to flag and eliminate risks like aggregation or poor expression before physical manufacturing begins.

Targeted Precision Oncology Portfolio
Tumor-Associated Antigens (TAAs) represent the frontier of precision oncology. Our single-domain antibody assets are specifically engineered as modular building blocks, optimized for integration into next-generation modalities including Antibody/Nanobody-Drug Conjugates (ADCs/NDCs), CAR-T/NK cell therapies, and multispecific biologics.

Platform Benchmarks Across Our Pipeline

Every asset in our pipeline has been computationally and empirically screened to meet rigorous clinical-grade criteria:
• High Affinity: Dissociation constants (KD) finely tuned down to sub-nanomolar ranges for superior target engagement.
• Cellular Efficacy: Robust functional activity and target-specific binding validated in advanced screening assays.
• Superior Biophysical Profiles: Exceptional thermal stability (with melting temperatures Tm ensuring high manufacturability and flexible formulation profiles.

We maintain an active, high-value portfolio of candidate leads optimized for both hematologic and solid tumors 

The multiple anti-TAA nanobodies have been developed and confirmed by lab in vitro and in vivo experiment, which have demonstrated the high quality and drug developability nanobody drugs  to move forward CMC/IND.   The Assets have been patented and ready  for Licensing & Co-Development, which have been initiating and evaluating by Dynamicure Bio and HualanBio